Travere Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · San Diego, CA
TVTX chart
What traders are saying about $TVTX
Latest postsTravere Therapeutics, Inc. news
- Travere Therapeutics at guggenheim conference: filspari drives growth By Investing.com
Investing.com India ·
- Travere Therapeutics (TVTX) Returned To Losses In Q3, Is A 31% Discount Warranted?
Simply Wall St ·
- Travere Therapeutics (NDQ:TVTX): Building the foundational therapy for rare kidney disease
Stocks Down Under ·
- JP Morgan maintains Travere Therapeutics at Overweight, lowers price target to $86 from $90
TradingView ·
- Travere Therapeutics Stock Price Forecast. Should You Buy TVTX?
StockInvest.us ·
- Leerink Partners maintains Travere Therapeutics at Outperform, lowers price target to $67 from $78
TradingView ·
- FMR's amended stake report gives it voting power over 4.98M Travere Therapeutics (TVTX) shares.
Stock Titan ·
- TVTX Stock Price and Chart — NASDAQ:TVTX
TradingView ·
- Analysts Are Bullish on These Healthcare Stocks: Neurocrine (NBIX), Travere Therapeutics (TVTX)
The Globe and Mail ·
- Why Travere Therapeutics Stock Is Up 6.1% And What's Next
Simply Wall St ·
- Canaccord Genuity maintains Travere Therapeutics at Buy, raises price target to $72 from $70
TradingView ·
- Bank of America Securities Sticks to Their Buy Rating for Travere Therapeutics (TVTX)
The Globe and Mail ·
Travere Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $490.7M | $233.2M | $145.2M | $109.5M |
| Net income | -$25.5M | -$321.5M | -$111.4M | -$278.5M |
| Diluted EPS | $-0.29 | $-4.08 | $-1.50 | $-4.37 |
| Total assets (year end) | $605.2M | $594.1M | $788.9M | $672.6M |
| Cash and equivalents (year end) | $93.0M | $58.5M | $58.2M | $61.7M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Travere Therapeutics, Inc.
- Ticker
- TVTX (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- San Diego, CA
- Incorporated in
- CA
- Fiscal year end
- December 31
- SEC CIK
- 1438533
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
Frequently asked questions
What exchange is Travere Therapeutics, Inc. listed on?
Travere Therapeutics, Inc. trades on the Nasdaq under the ticker symbol TVTX.
What industry is Travere Therapeutics, Inc. in?
Travere Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Travere Therapeutics, Inc. headquartered?
Travere Therapeutics, Inc.'s business address on file with the SEC is in San Diego, CA.
When does Travere Therapeutics, Inc.'s fiscal year end?
Travere Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Travere Therapeutics, Inc. report?
Travere Therapeutics, Inc. reported $490.7M in revenue for calendar year 2025, according to its SEC filings.